Opko Health Inc (OPK) : 4 analysts are covering Opko Health Inc (OPK) and their average rating on the stock is 2, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Opko Health Inc (OPK) stock is expected to deviate a maximum of $5.03 from the average target price of $15.33 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $20 and the most muted being $10.
Also, Deutsche Bank maintains its rating on Opko Health Inc (NYSE:OPK). The global brokerage major lowers the current price target from $11 per share to $10 per share. Analysts at the Deutsche Bank have a current rating of Hold on the shares. The rating by the firm was issued on June 16, 2016.
Opko Health Inc (NYSE:OPK): After opening at $10.2, the stock dipped to an intraday low of $10.11 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $10.31 and the buying power remained strong till the end. The stock closed at $10.22 for the day, a gain of 0.29% for the day session. The total traded volume was 3,793,068. The stocks close on the previous trading day was $10.19.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.